Interferon alfa-2b
- Generic Name
- Interferon alfa-2b
- Brand Names
- Intron A
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98530-12-2
- Unique Ingredient Identifier
- 43K1W2T1M6
- Background
Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
- Indication
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Condylomata Acuminata (External), Follicular Non-Hodgkin's Lymphoma, Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Malignant Melanoma
- Associated Therapies
- -
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
- Conditions
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2006-01-09
- Lead Sponsor
- National Cancer Institute, Milan
- Target Recruit Count
- 150
- Registration Number
- NCT00273247
- Locations
- 🇮🇹
National Cancer Institute, Milan, Italy
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2005-12-01
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 84
- Registration Number
- NCT00234182
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 898
- Registration Number
- NCT00221702
- Locations
- 🇫🇷
APHM, dermatology, Marseille, France
Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression
- Conditions
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2005-08-16
- Target Recruit Count
- 200
- Registration Number
- NCT00125814
- Locations
- 🇫🇷
Service de Medecine Interne, Clamart, France
A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Miami
- Registration Number
- NCT00002270
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-04-30
- Target Recruit Count
- 10
- Registration Number
- NCT00001035
- Locations
- 🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸USC CRS, Los Angeles, California, United States
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000694
- Locations
- 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001114
- Locations
- 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇵🇷Puerto Rico-AIDS CRS, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.